Psychosocial issues in cancer genetics: Current status and future directions

Acta Oncologica

Volumn 42, Issue 4, 2003, Pages 276-286

  Bleiker, Eveline M A ^a   Hahn, Daniela E E ^a   Aaronson, Neil K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; GENETIC ENGINEERING; HEALTH INSURANCE; SOCIAL ASPECTS; TUMORS;

GENETIC TESTING;

ONCOLOGY;

CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DIAGNOSTIC TEST; DISTRESS SYNDROME; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GUILT; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MASTECTOMY; ONCOGENE; OVARIECTOMY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOCIAL PSYCHOLOGY;

ATTITUDE TO HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; NEOPLASMS; PSYCHOLOGY;

EID: 0037488360     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004391     Document Type: Review

References (82)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
2. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
3. Coyne JC, Benazon NR, Gaba CG, Calzone K, Weber BL. Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families. J Consult Clin Psychol 2000; 68: 864-74.
4. Marteau TM, Croyle RT. The new genetics. Psychological responses to genetic testing. Br Med J 1998; 316: 693-6.
5. Craufurd D, Dodge A, Kerzin-Storrar L, Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 1989; 2: 603-5.
6. Aktan-Collan K, Mecklin JP, Jarvinen H, et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 2000; 89: 44-50.
7. Julian-Reynier C, Sobol H, Sevilla C, Nogues C, Bourret P. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology 2000; 9: 504-10.
8. Hagoel L, Dishon S, Almog R, Silman Z, Bisland-Becktell S, Rennert G. Proband family uptake of familial-genetic counselling. Psychooncology 2000; 9: 522-7.
9. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355: 2015-20.
10. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. a prospective study of patient decision making and outcomes. JAMA 1996; 275: 1885-92.
11. Lerman C, Schwartz MD, Lin TH, Hughes C, Narod S, Lynch HT. The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol 1997; 65: 414-20.
12. Patenaude AF, Schneider KA, Kieffer SA, et al. Acceptance of invitations for p53 and BRCA1 predisposition testing: factors influencing potential utilization of cancer genetic testing. Psycho-oncology 1996; 5: 241-50.
13. Biesecker BB, Ishibe N, Hadley DW, et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000; 93: 257-63.
14. Cappelli M, Surh L, Humphreys L, et al. Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin Genet 1999; 55: 419-30.
15. Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92: 959-68.
16. Hodgson SV, Haites NE, Caligo M, et al. A survey of the current clinical facilities for the management of familial cancer in Europe. European Union BIOMED II Demonstration Project: Familial Breast Cancer: audit of a new development in medical practice in European centres. J Med Genet 2000; 37: 605-7.
17. Geller G, Doksum T, Bernhardt BA, Metz SA. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions. Cancer Epidemiol Biomarkers Prev 1999; 8: 377-83.
18. Croyle RT, Lerman C. Risk communication in genetic testing for cancer susceptibility. J Natl Cancer Inst Monogr 1999; 25: 59-66.
19. Bleiker EM, Aaronson NK, Menko FH, et al. Genetic counseling for hereditary cancer: a pilot study on experiences of patients and family members. Patient Educ Couns 1997; 32: 107-16.
20. Kash KM. Psychosocial and ethical implications of defining genetic risk for cancers. Ann NY Acad Sci 1995; 768: 41-52.
21. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731-8.
22. Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med 2002; 54: 1463-70.
23. DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J, Trijsburg RW. Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup. Am J Med Genet 1998; 75: 62-74.
24. Tibben A, Roos RA, Niermeijer MF. Psychological consequences of presymptomatic testing for Huntington's disease. Lancet 1997; 349: 809.
25. Kash KM, Holland JC, Osborne MP, Miller DG. Psychological counseling strategies for women at risk of breast cancer. Monogr Natl Cancer Inst 1995; 17: 73-9.
26. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12: 843-50.
27. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-7.
28. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-64.
29. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22.
30. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-9.
31. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
32. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst 1995; 17: 33-5.
33. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71: 2751-5.
34. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998; 16: 979-85.
35. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336: 1465-71.
36. Eisinger F, Geller G, Burke W, Holtzman NA. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 1999; 353: 919-20.
37. Newman L. French national ad hoc committee strongly resists prophylactic mastectomy. J Natl Cancer Inst 2001; 93: 339.
38. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000; 31: 75-80.
39. Lynch HT, Lynch JF, Rubinstein WS. Prophylactic mastectomy: obstacles and benefits. J Natl Cancer Inst 2001; 93: 1586-7.
40. Hatcher MB, Fallowfield L, A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. Br Med J 2001; 322: 76.
41. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995; 24: 412-9.
42. Borgen PI, Hill AD, Tran KN, et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998; 5: 603-6.
43. Hopwood P, Lee A, Shenton A, et al. Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. Psychooncology 2000; 9: 462-72.
44. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000; 284: 319-24.
45. Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med 2001; 46: 87-94.
46. Meiser B, Tiller K, Gleeson MA, Andrews L, Robertson G, Tucker KM. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 2000; 9: 496-503.
47. Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology 2000; 9: 486-95.
48. Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001; 10: 231-41.
49. Hollenstein J, Bleiker EMA, Valdimarsdottir HB, van Beurden M, Aaronson NK. Prevention of hereditary ovarian cancer: choices and consequences. Psycho-oncology 2001; 10: S40.
50. Bassford TL, Hauck L. Human genome project and cancer: the ethical implications for clinical practice. Semin Oncol Nurs 1993; 9: 134-8.
51. Marteau TM, Anionwu W. Evaluating carrier testing: objectives and outcomes. In: Marteau T, Richards M, eds. The troubled helix. Social and psychological implications of the new human genetics. Cambridge: University Press, 1996: 123-39.
52. Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992; 50: 476-82.
53. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002; 11: 79-87.
54. van Maarle M, Stouthard M, van Loosdrecht S, Marang-van de Mheen P. Genetische screening en verzekeringen:dragers van FH ondervinden problemen. Medisch contact 2000; 55: 360-2.
55. Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science 1996; 274: 621-4.
56. Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology 1998; 7: 402-12.
57. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992; 84: 24-30.
58. Cull A, Fry A, Rush R, Steel CM. Cancer risk perceptions and distress among women attending a familial ovarian cancer clinic. Br J Cancer 2001; 84: 594-9.
59. Watson M, Lloyd S, Davidson J, et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer 1999; 79: 868-74.
60. Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S. Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer 2002; 86: 43-50.
61. Bleiker EM, Grosfeld FJ, Hahn DE, Honing C. Psychosocial care in family cancer clinics in The Netherlands: a brief report. Patient Educ Couns 2001; 43: 205-9.
62. Decruyenaere M, Evers-Kiebooms G, Denayer L, et al. Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling. Eur J Hum Genet 2000; 8: 130-6.
63. DudokdeWit AC, Tibben A, Frets PG, et al. BRCA1 in the family: a case description of the psychological implications. Am J Med Genet 1997; 71: 63-71.
64. Tjemsland L, Soreide JA, Malt UF. Posttraumatic distress symptoms in operable breast cancer III: status one year after surgery. Breast Cancer Res Treat 1998; 47: 141-51.
65. Bleiker EMA, Pouwer F, van der Ploeg HM, Leer J-WH, Ader HJ. Psychological distress two years after diagnosis of breast cancer: frequency and prediction. Patient Educ Couns 2000; 40: 209-17.
66. Northouse LL, Templin T, Mood D, Oberst M. Couples' adjustment to breast cancer and benign breast disease: a longitudinal analysis. Psycho-oncology 1998; 7: 37-48.
67. DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J. Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. J Med Genet 1998; 35: 745-54.
68. Wellisch DK, Gritz ER, Schain W, Wang HJ, Siau J. Psychological functioning of daughters of breast cancer patients. Part ii: characterizing the distressed daughter of the breast cancer patient. Psychosomatics 1992; 33: 171-9.
69. Hopwood P, Shenton A, Lalloo F, Evans DG, Howell A. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet 2001; 38: 139.
70. Erblich J, Bovbjerg DH, Valdimarsdottir HB. Looking forward and back: distress among women at familial risk for breast cancer. Ann Behav Med 2001; 22: 53-9.
71. Dudok-de Wit C, Meijers-Heijboer EJ, Tibben A, et al. Effect on a Dutch family of predictive DNA-testing for hereditary breast and ovarian cancer. Lancet 1994; 344: 197.
72. Lerman C, Hughes C, Lemon SJ, et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998; 16: 1650-4.
73. Grosfeld FJ, Lips CJ, Ten Kroode HF, Beemer FA, Van Spijker HG, Brouwers-Smalbraak GJ. Psychosocial consequences of DNA analysis for men type 2. Oncology (Huntingt) 1996; 10: 141-6.
74. Davison C. Predicitive genetics: the cultural implications of supplying probable futures. In: Marteau T, Richards M, eds. The troubled helix. Social and psychological implications of the new human genetics. Cambridge: University Press, 1996: 317-30.
75. Wellisch DK. Families and cancer. Psycho-oncology 1998; 7: 1-2.
76. Northouse LL. Breast cancer in younger women: effects on interpersonal and family relations. Monogr Natl Cancer Inst 1994; 16: 183-90.
77. Northouse LL. The impact of cancer in women on the family. Cancer Pract 1995; 3: 134-42.
78. Horowitz M, Wilner N, Alvarez W. Impact of the Event Scale: a measure of subjective stress. Psychosom Med 1979; 41: 209-18.
79. Spielberger CD. Manual for the state-trait anxiety inventory Stai-form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
80. Radloff LS. A self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385-401.
81. Marteau TM, Lerman C. Genetic risk and behavioural change. Br Med J 2001; 322: 1056-9.
82. Croyle RT, Lerman C. Risk communication in genetic testing for cancer susceptibility. J Natl Cancer Inst Monogr 1999; 25: 59-66.